 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 5 | 1/1 | 返回列表 |
| 查看: 660 | 回復: 2 | |||
| 當前只顯示滿足指定條件的回帖，點擊這里查看本話題的所有回帖 | |||
狼行拂曉榮譽版主 (著名寫手)
~~~~
|
[交流]
Novo Nordisk to Initiate Phase 3a Development of Oral Semaglutide 已有2人參與
|
||
|
Novo Nordisk to Initiate Phase 3a Development of Oral Semaglutide, a Once-Daily Oral GLP-1 Analogue Bagsværd, Denmark, 26 August 2015 - Novo Nordisk today announced the decision to initiate a phase 3a programme with oral semaglutide; a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide. The decision follows the encouraging results of the proof-of-concept phase 2 trial announced on 20 February 2015 and the subsequent consultations with regulatory authorities. Novo Nordisk intends to initiate a global phase 3a programme, named PIONEER, comprising seven trials with approximately 8,000 people with type 2 diabetes. The PIONEER programme will include six safety and efficacy trials and one trial for evaluating the cardio-vascular safety of oral semaglutide. The first trial in the programme is planned for initiation in first quarter of 2016 and will investigate the efficacy and safety of once-daily oral semaglutide doses of 3 mg, 7 mg and 14 mg, compared to once-daily oral anti-diabetic sitagliptin dose of 100 mg. The remaining six trials of the PIONEER programme are all expected to be initiated during 2016. In order to meet capacity requirements for current and future diabetes care products, including oral semaglutide, Novo Nordisk expects to invest an estimated 2 billion US dollars over the coming five years in two new production facilities; a new production facility for a range of active pharmaceutical ingredients in Clayton, North Carolina, US and a new drug-product facility in Måløv, Denmark. The final design and cost of the new production facilities will be presented for approval by the company's board of directors in 2016. "Delivering protein-based medicine like semaglutide in the form of a tablet and producing it on a large scale is a major challenge, and with the announcement today we have reached a significant milestone towards achieving that goal", said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "We are excited about the opportunities oral semaglutide represents as a new oral anti-diabetic agent to further improve type 2 diabetes treatment". About Semaglutide Semaglutide (NN9924) is a new glucagon-like peptide-1 (GLP-1) analogue that can help people with type 2 diabetes achieve substantial lowering of blood glucose with a low risk of hypoglycaemia. In addition, semaglutide induces weight loss by decreasing appetite and food intake. The oral formulation of semaglutide is provided in a tablet formulation with SNAC, an absorption-enhancing excipient included in the Eligen® Carrier Concept. The Eligen® technology is licenced from Emisphere Technologies, Inc. Source: Novo Nordisk Posted: August 2015 |
回復此樓» 猜你喜歡
求助各位大佬，載藥PLGA納米粒易團聚該如何解決？
已經(jīng)有0人回復
-
跪求一支AAV293細胞
已經(jīng)有1人回復
-
藥物學論文潤色/翻譯怎么收費?
已經(jīng)有117人回復
-
透明質酸 甲基丙烯酸酐
已經(jīng)有0人回復
-
305材料專碩調(diào)劑
已經(jīng)有12人回復
-
CSC改派-博士生交流訪學
已經(jīng)有19人回復
-
中山大學-第七醫(yī)院-招科研助理1名（基因設計和克隆、RNA合成）
已經(jīng)有0人回復
-
中山大學-第七醫(yī)院-招科研助理1名（基因設計和克隆、RNA合成）
已經(jīng)有1人回復
-
巴黎薩克雷大學與國家留學基金委合作博士研究生項目-脂質納米藥物/生物材料/多酚遞送
已經(jīng)有10人回復
-
錦州醫(yī)科大學藥用生物材料（專業(yè)代碼1007Z1）招收調(diào)劑考生
已經(jīng)有0人回復
-
錦州醫(yī)科大學藥用生物材料（專業(yè)代碼1007Z1）招收調(diào)劑考生
已經(jīng)有1人回復
GeniusCai
銅蟲 (初入文壇)
- 應助: 0 (幼兒園)
- 金幣: 716.1
- 帖子: 42
- 在線: 16.2小時
- 蟲號: 2362462
- 注冊: 2013-03-20
- 性別: GG
- 專業(yè): 藥物化學
3樓2015-09-10 22:43:50
voyager88
金蟲 (著名寫手)
- DRDEPI: 11
- 應助: 584 (博士)
- 金幣: 2387
- 散金: 4182
- 紅花: 338
- 帖子: 1994
- 在線: 551.7小時
- 蟲號: 1259270
- 注冊: 2011-04-08
- 專業(yè): 藥劑學
2樓2015-09-01 13:52:11
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 材料考研調(diào)劑 +3 | xwt。 2026-03-19 | 3/150 |
|
|---|---|---|---|---|
|
|
[考研] 一志愿吉林大學材料學碩321求調(diào)劑 +6 | Ymlll 2026-03-18 | 9/450 |
|
|
[考研] 267一志愿南京工業(yè)大學0817化工求調(diào)劑 +10 | SUICHILD 2026-03-12 | 10/500 |
|
|
|
[考研] 求材料調(diào)劑 +10 | 隔壁陳先生 2026-03-12 | 10/500 |
|
|
|
[考研] 一志愿中國海洋大學，生物學，301分，求調(diào)劑 +4 | 1孫悟空 2026-03-17 | 4/200 |
|
|
|
[考研] 化學工程321分求調(diào)劑 +15 | 大米飯！ 2026-03-15 | 18/900 |
|
|
|
[考研] 08工科 320總分 求調(diào)劑 +5 | 梨花珞晚風 2026-03-17 | 5/250 |
|
|
|
[考研] 298-一志愿中國農(nóng)業(yè)大學-求調(diào)劑 +7 | 手機用戶 2026-03-17 | 7/350 |
|
|
|
[考研] 材料，紡織，生物（0856、0710），化學招生啦 +3 | Eember. 2026-03-17 | 9/450 |
|
|
|
[考研] 268求調(diào)劑 +8 | 一定有學上- 2026-03-14 | 9/450 |
|
|
|
[考研] 一志愿蘇州大學材料工程（085601）專碩有科研經(jīng)歷三項國獎兩個實用型專利一項省級立項 +6 | 大火山小火山 2026-03-16 | 8/400 |
|
|
|
[考研] 考研調(diào)劑 +3 | 淇ya_~ 2026-03-17 | 5/250 |
|
|
|
[考研] 326求調(diào)劑 +4 | 諾貝爾化學獎覬?/a> 2026-03-15 | 7/350 |
|
|
|
[考研] 085600調(diào)劑 +5 | 漾漾123sun 2026-03-12 | 6/300 |
|
|
|
[考研] 0703化學調(diào)劑 290分有科研經(jīng)歷，論文在投 +7 | 膩膩gk 2026-03-14 | 7/350 |
|
|
|
[考研] 招收0805（材料）調(diào)劑 +3 | 18595523086 2026-03-13 | 3/150 |
|
|
|
[考研] 求材料調(diào)劑 085600英一數(shù)二總分302 前三科235 精通機器學習 一志愿哈工大 +4 | 林yaxin 2026-03-12 | 4/200 |
|
|
|
[考研] 求調(diào)劑 +5 | 一定有學上- 2026-03-12 | 5/250 |
|
|
|
[考研] 工科材料085601 279求調(diào)劑 +8 | 困于星晨 2026-03-12 | 10/500 |
|
|
|
[考研] 289求調(diào)劑 +3 | 李政瑩 2026-03-12 | 3/150 |
|